Trial Profile
A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy of Dupilumab (Anti-IL4a) in Subjects With Eosinophilic Gastritis
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Feb 2024
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary)
- Indications Eosinophilic gastroenteritis
- Focus Therapeutic Use
- Acronyms DEGS
- 01 Feb 2024 According to a Sanofi media release, first participant has been treated.
- 04 Jan 2024 Planned End Date changed from 1 Apr 2024 to 20 Nov 2024.
- 04 Jan 2024 Planned primary completion date changed from 1 Oct 2023 to 10 Mar 2024.